57 results about "ECM Protein" patented technology

The application belongs to the technical field of biomedical materials, and discloses a collagen-based double-network porous hydrogel scaffold capable of recruiting endogenous stem cells and a construction method and application thereof. The scaffold takes collagen II (Col-II) and oxidized methyl acrylated hyaluronic acid (AHAMA) as an organic phase, and is constructed into a physical / chemical double-network structure through Schiff base dynamic crosslinking and ultraviolet light-induced methacryl radical polymerization. An air-in-water emulsion template method is used to form a through-porous structure, and 5' aldehyde-modified nucleic acid aptamer Apt19S is anchored in the scaffold network to achieve specific recruitment of endogenous pluripotent stem cells. The scaffold has excellent mechanical properties, a biomimetic extracellular matrix microenvironment and a targeted stem cell recruitment function, can effectively promote the directional differentiation of stem cells into chondrocytes, avoids the immune rejection and ethical issues caused by exogenous stem cell transplantation, and is suitable for the field of articular cartilage defect repair.

The present application relates to cell preparation process in the field of bioengineering, disclose a kind of high-efficiency preparation mouse primary hepatocyte method, comprising: perfusion needle is placed in reverse direction to liver direction through inferior vena cava, utilize the blood vessel clamp with elastic micro-tooth damping surface to lock the perfusion needle and inferior vena cava wall;The overflow damping of hepatic portal vein outflow end is dynamically regulated by blood vessel clamp, to construct controlled positive pressure permeation environment in liver vascular bed;Collagenase solution is radially permeated to liver parenchyma using the environment, the present application makes enzyme solution radial deflection and cross blood sinus barrier into di's cavity by constructing micro-pressure environment, eliminate the digestion dead zone originally due to flow path preference, ensure that enzyme molecule and extracellular matrix are uniformly contacted in global dimension, realize the collaborative promotion of tissue cutting efficiency and total amount of cell release, ensure that the output cell population has highly consistent physiological state.

The present application relates to the field of biotechnology, in particular to a kit based on functionalized magnetic beads and application thereof in the field of stem cells. The functionalized magnetic beads of the present application are loaded with extracellular matrix proteins on the surface, and the extracellular matrix proteins are selected from collagen. The functionalized magnetic beads of the present application realize efficient capture and enrichment of collagen-bound transmembrane proteins, combined with mass spectrometry identification, and are suitable for screening stem cell transmembrane proteins, studying the action sites of stem cells and matrix, or developing drugs targeting stem cells. The kit and method of the present application have the technical advantages of simple operation, good stability and strong specificity, and provide a powerful tool for systematic study of the cell-matrix interaction mechanism mediated by stem cell transmembrane proteins.

This invention discloses a method for preparing a co-loaded dual-gene targeted delivery system and its application, involving the construction and preparation of a dual-gene (pHNF4α, pFOXA3) delivery system. This delivery system can target myofibroblasts (MFs) and activated hepatic stellate cells (aHSCs) and can be used for gene therapy of liver fibrosis. This invention synthesizes the targeting carrier material PEI. 25K -PEG 2K -pPB, through electrostatic adsorption, combines with pHNF4α and pFOXA3 to form a co-loaded dual-gene targeted delivery system, F4α / A3@PP-pPB. This delivery system, through the targeting group pPB, binds to MFs (metacellular matrix cells) that lead to excessive accumulation of extracellular matrix in fibrotic livers and to PDGFR (polydimethylformamide) highly expressed on the surface of aHSCs. On the one hand, it inhibits the activation of aHSCs; on the other hand, it transdifferentiates MFs into hepatocyte-like cells (iHep). These two modes, while combating liver fibrosis, can also achieve a certain degree of liver function reconstruction through transdifferentiated iHep cells, providing new ideas and methods for the effective treatment of liver fibrosis.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

This invention belongs to the field of biomedical technology and discloses the application of KDELR3 inhibitors in the preparation of drugs for the prevention and / or treatment of individual fibrotic diseases. In a wild-type mouse model of pulmonary fibrosis, compared with the control group receiving intratracheal injection of Scr siRNA, intratracheal injection of KDELR3 siRNA significantly reduced the degree of fibrosis in the mouse lung tissue. KDELR3 inhibition significantly reduced collagen deposition and improved lung tissue structural damage. Further mechanistic studies showed that KDELR3 inhibitors can inhibit the differentiation of fibroblasts into myofibroblasts, thereby reducing the production of fibrosis-related extracellular matrix. These results indicate that KDELR3 is a key molecule regulating the occurrence and development of fibrosis, and drugs that can inhibit KDELR3 expression or activity can be used to prevent and treat various fibrotic diseases, including pulmonary fibrosis, laying the foundation for the development of novel drugs that are effective and safe in treating fibrotic diseases.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The present invention discloses the use of Avn Anthramides C (Avn C) as an inducer of chondrocytic differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapy. By employing Avn C treatment, MSCs exhibit enhanced chondrocytic differentiation and elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably Collagen Type II (COL2A1). Furthermore, when Avn C is used in combination with Chondroitin Sulfate (CS), a synergistic effect is observed, leading to upregulation of the transcriptional activity state of SOX9, a key regulator of chondrogenesis. The disclosed invention shows significant improvements in mRNA gene expression (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of a composition in the preparation of a drug for treating diabetic wounds. The composition comprises the following components: *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone, with a mass ratio of 1:0.1-0.25:0.02-0.05. In this composition, *Artemisia capillaris* exosomes can penetrate the thickened inflammatory exudate layer and glycosylated extracellular matrix of diabetic wounds, reshaping the wound's immune repair microenvironment, promoting fibroblast activation and proliferation, regulating collagen synthesis and deposition, and reducing scar hyperplasia. 3-hydroxymorinogenone can increase vascular endothelial growth factor, promote angiogenesis, and thus promote the repair and healing of diabetic wounds. The synergistic effect of *Artemisia capillaris* exosomes, epi-suberol, and 3-hydroxymorinogenone in this composition significantly shortens the healing cycle of difficult-to-heal diabetic wounds and improves the quality of wound healing.

The present application relates to the technical field of biotechnology, and provides a CRISPR-Cas9 system sgRNA sequence capable of efficiently targeting and knocking out a human SPARC gene, a recombinant vector containing the sgRNA sequence, and a construction method and application demonstration of a SPARC gene knockout cell model.The sgRNA sequence can mediate a high-specificity and high-efficiency SPARC gene knockout effect, effectively solving the problems of strong blindness, low screening efficiency and lack of reliable tool sequences in the prior art sgRNA design for the gene.The SPARC gene knockout Hela cell line constructed by using the sgRNA sequence and the recombinant vector has important technical value and practical significance for studying the extracellular matrix network regulation and cell migration ability.

This invention discloses carboxymethyl sucrose amino acid salts, their preparation, compositions, and applications. The salts are prepared from carboxymethyl sucrose and arginine, or carboxymethyl sucrose and glycine, through a chemical reaction. The resulting salts undergo a series of processes including primary alcohol precipitation, redissolution, secondary alcohol precipitation, redissolution, tertiary alcohol precipitation, soaking, pulverization, filtration, and drying to obtain carboxymethyl sucrose arginine and carboxymethyl sucrose glycine salts. A composition is prepared by mixing these two salts. Both salts and the composition significantly inhibit the activity of matrix metalloproteinase 1 and promote the expression of type I collagen, thus delaying aging by maintaining the stability of collagen morphology and structure in the extracellular matrix. The preparation method of this invention is simple and the process conditions are mild. The product has the advantages of being weakly acidic, gentle on the skin, highly safe, and having good anti-aging effects. It can be widely used in skin care cosmetics and has promising application prospects.

The present application relates to the technical field of intervertebral disc degeneration treatment and drug delivery, and discloses an injectable oxynate sodium functionalized hydrogel microsphere loaded with TGFbeta3 and application, by loading glycolysis inhibitor SO in the GelMA microsphere matrix and post-adsorbing TGFbeta3, on the one hand, SO is used to inhibit the excessive active glycolysis in the degenerative microenvironment, reduce lactic acid accumulation and relieve inflammation, on the other hand, TGFbeta3 is used to effectively promote the synthesis of collagen and proteoglycan, both of which synergistically act from the two aspects of metabolic regulation and matrix synthesis, and jointly promote the recovery of intervertebral disc homeostasis, therefore, the oxynate sodium functionalized microsphere loaded with TGFbeta3 constructed by the present application can realize the synergistic treatment of multiple targets and multiple pathways by synchronously delivering metabolic regulators and synthesis promoters, so as to more effectively delay or reverse the intervertebral disc degeneration process, and finally achieve the beneficial effect of the double repair effect of simultaneously regulating abnormal glycolysis metabolism of degenerative nucleus pulposus cells and promoting extracellular matrix synthesis.

This invention belongs to the technical field of 3D printing of biological tissues and organs, and discloses a biomimetic valve multi-nozzle 3D bioprinted scaffold and its application. The scaffold, from bottom to top, comprises a firmly connected elastin layer, a polysaccharide layer, and a collagen fiber layer. Each layer is constructed by alternating 3D printing of at least two materials; one of these materials is a photocurable hydrogel material providing mechanical support, and the other is a photocurable hydrogel material mixed with bioactive substances. Furthermore, the bioactive substances used in the elastin layer, polysaccharide layer, and collagen fiber layer are different from each other. This invention improves the structure and composition of the 3D bioprinted scaffold, creating a biomimetic three-layer structure and composition for a valve. The scaffold, designed with a three-layer structure of elastin, polysaccharide, and collagen fiber layers, provides cells with a specific sensory microenvironment, stimulating them to secrete corresponding extracellular matrix and completing extracellular matrix remodeling.

Disclosed is an artificial adipose tissue comprising a three-dimensional tissue comprising: a population of cells including an adipocyte; and a fragmented extracellular matrix.

The application discloses an integrin-targeting peptide-collagenase drug combination and a drug composition constructed by the integrin-targeting peptide-collagenase drug combination. The drug combination can effectively block mechanical signals and biochemical signals mediating fibrosis, efficiently inhibit fibroblast activation, reduce the secretion of extracellular matrix proteins, and reshape the fibrotic microenvironment. Efficient reduction of fibrosis can promote the penetration of subsequent therapeutic drugs, and has a cascade penetration effect. The constructed drug composition can synergistically deliver integrin-targeting peptides and collagenase, and after release, the integrin-targeting peptides and collagenase can synergistically act in the form of free molecules in fibrotic lesions, thereby providing a new strategy for efficient delivery of fibrosis treatment drugs.

This invention belongs to the field of bioengineering and functional skincare formulation technology, specifically relating to a dual-effect anti-aging freeze-dried composition for reversing photoaging and endogenous aging, and its application. The composition of this invention, based on the mass percentage of the original solution before freeze-drying, contains 3-8% photorepair enzymes, 15-25% recombinant collagen, 62-75% ternary freeze-drying protectant, 0.5-0.9% sodium chloride, and the balance being buffer solution. The ternary freeze-drying protectant includes fillers, vitreous-forming agents, and antioxidants. This invention repairs UV-induced DNA damage (such as cyclobutanepyrimidine dimers) through photorepair enzymes, while simultaneously utilizing recombinant collagen to remodel the extracellular matrix microenvironment, providing integrin adhesion signals, thus synergistically reversing skin photoaging and endogenous aging. The final composition obtained by this invention has good reconstitution properties and can be used to prepare anti-aging cosmetics such as lotions, serums, and creams, achieving highly effective and safe anti-aging effects on the skin.

The application discloses a multifunctional gradient structure artificial skin and a preparation method and application thereof, and belongs to the technical field of biomaterials and biomedical engineering. The upper layer of the application is a silica gel layer, which is used for simulating epidermis to keep a moist environment of a wound and simultaneously plays a barrier role; the intermediate layer is a degradable polymer / natural bioactive protein composite layer, which is used for enhancing mechanical properties; and the lower layer is a hydrogel layer, which is formed by cross-linking hyaluronic acid and carboxymethyl chitosan to form a Schiff base bond and then cross-linking collagen through catalysis. The composition of the hydrogel layer is a component of an extracellular matrix, and the three-dimensional network structure formed is beneficial to cell growth, can simulate a dermis layer to play a function of promoting tissue regeneration and remodeling, and finally the artificial skin with good mechanical strength, capable of preventing wound infection and promoting wound healing is obtained.

Methods, articles, and fluidic systems for sorting and growing organoids are generally provided. Organoids may be useful for various applications, such as certain types of biological studies, or for testing the biocompatibility and performance of drugs. However, conventional methods often struggle to identify, isolate, and use organoids. In some embodiments, using the droplet-based methods and associated articles and fluidic systems provided herein, organoids may be selected, isolated, and studied.

Aspects of the present disclosure relate to the discovery that antagonizing pyruvate carboxylase and glutaminase inhibits cell proliferation and extracellular matrix production. Thus, methods and compositions disclosed herein may be used to treat fibrotic disease and cancer by inhibiting cell proliferation and extracellular matrix production.

The application relates to the field of tissue engineering and regenerative medicine, and particularly discloses a cell-extracellular matrix complex for hair follicle regeneration and a preparation method thereof. The complex comprises autologous hair follicle stem cells, a human scalp-derived acellular ECM scaffold, time-sequentially added growth factors and an anti-scarring component. In preparation, the autologous hair follicle stem cells are first induced by BMP4 and TGF-beta 1 in cooperation, then inoculated into the human scalp-derived acellular ECM scaffold, and the complex is constructed under dynamic culture conditions, and VEGF is added to promote vascularization. The complex can efficiently form a structure-intact hair papilla-like tissue, has good biocompatibility, low immunogenicity and anti-scarring characteristics, and is significantly superior to a traditional collagen scaffold system. The application provides a new regeneration treatment strategy with clear clinical transformation prospects for scaleable preparation for androgenetic alopecia and other hair follicle deficiency diseases.

The application discloses high-adhesion modified mesenchymal stem cells and application thereof in preparation of a medicine for treating intrauterine adhesion. The modified mesenchymal stem cells are genetically engineered to overexpress integrin alpha 2 subunit and / or integrin alpha 5 subunit, thereby enhancing the adhesion capacity to the extracellular matrix (collagen and fibronectin) of the endometrium. In vitro experiments show that the initial adhesion rate, liquid flushing resistance and anoikis resistance of the modified MSCs are significantly better than those of common MSCs. When used in combination with the "dynamic culture and drug delivery device for intrauterine adhesion treatment" applied by the inventor on the same day, the retention rate of the modified MSCs in the simulated intrauterine dynamic culture environment is significantly improved. Animal experiments show that the modified MSCs in combination with the device can significantly promote endometrial regeneration, inhibit fibrosis and improve the pregnancy rate. The application solves the core bottleneck of low cell retention rate and short survival time in the MSC transplantation treatment of intrauterine adhesion by enhancing the adhesion capacity of the MSCs, and forms a complete treatment scheme in cooperation with the device, thereby having a good clinical application prospect.

The present application relates to a kind of anti-wrinkle firming compositions acting on ECM and its application, the composition includes the following components: sodium can pull acid, cordyceps extract, black sporocarp extract, carrot root extract and spurflower / leaf / stem extract, the composition is targeted to the core logic acting on skin extracellular matrix (ECM), from free radical scavenging and collagen synthesis promotion two dimensions solve the technical defects of traditional anti-aging product, finally realize anti-aging, firming, whitening and repair effect etc..

The embodiment of the application discloses a preparation method of humanized extracellular matrix, and belongs to the technical field of biomedical materials and tissue engineering. The method comprises the following steps: preparing human decellularized dermal matrix; preparing a concentrated solution of a condition medium rich in human active factors; constructing RGD-PLGA / BMP-2 nanocomposites; loading the concentrated solution of the condition medium into the human decellularized dermal matrix through vacuum negative pressure perfusion, and then anchoring the RGD-PLGA / BMP-2 nanocomposites, and cross-linking them twice through genipin to obtain the humanized extracellular matrix. Through the four-element strategy of decellularized matrix-active factor-nano-sustained release-two-stage cross-linking, the unity of low immunogenicity, high biological activity and spatiotemporal controllable release function is realized, and the humanized extracellular matrix can be applied to the fields of tissue engineering scaffolds, wound repair and bone defect filling.

The present application relates to a kind of multifunctional medical fiber membrane and its preparation method and application, the multifunctional medical fiber membrane is with including poly high molecular material, material with anionic group, collagen and ε-polylysine in it Material is raw material, using the electrospun fiber membrane prepared by conjugated electrospinning technology.This medical fiber membrane has the advantages of electrospun membrane and self-assembly membrane simultaneously, close to the structure of extracellular matrix, can provide a large number of cell contact points, provide better microenvironment for cell adhesion, proliferation, physiological function;It contains collagen and ε-polylysine in composition, can make it have good hydrophilicity and antibacterial property, the addition of material with anionic group makes collagen and ε-polylysine more stably combined on fiber membrane, so that it slowly releases, while its own good characteristics make product can be directly attached in clinical use, more effectively induce cell growth and tissue regeneration, and then effectively promote the repair of wound surface.

The application discloses a spoke-shaped decellularized cornea and a preparation method and application thereof, and belongs to the technical field of biomaterials and tissue engineering. The application realizes an orderly process of the phase change of water molecules along the temperature gradient direction by establishing a gradient temperature field from the periphery to the center of a sheet-shaped biological corneal tissue, and forms spoke-shaped microchannels in the cornea. The spoke-shaped microchannels can accelerate the decellularization process of the central region of the cornea, avoid excessive decellularization of the peripheral region of the cornea to cause excessive loss of bioactive components of the extracellular matrix, form a biomimetic migration path between the cornea and the receptor, facilitate the migration and infiltration of the cells of the receptor tissue into the cornea, promote the biological healing of the transplanted cornea and the limbus of the receptor cornea, and improve the biological stability of the transplanted cornea.

This invention discloses a biomimetic extracellular matrix composition, its preparation method, application, and cosmetics, belonging to the field of cosmetic technology. The composition comprises, by weight percentage, the following components: Type I collagen: 0.01%-0.5%, Type III collagen: 0.01%-0.3%, Type VII collagen: 0.005%-0.2%, Type XVII collagen: 0.005%-0.2%, elastin: 0.01%-0.3%, fibronectin: 0.005%-0.2%, moisturizing ingredients: 0.2%-2.0%, repair factors: 0.061%-0.8%, polypeptide ingredients: 0.02%-0.8%, β-Xylane: 0.5%-3.0%, excipients: 0%-5%, and the balance being water. This invention uses four types of collagen, elastin, and fibronectin as the core structure, and combines them with moisturizing ingredients, repair factors, and peptides to form a complete synergistic system. This system forms a multi-pathway, multi-level synergistic enhancement system that can biomimetically reconstruct the extracellular matrix structure of the entire skin layer, achieving six effects in one: anti-aging, firming, wrinkle reduction, repair, moisturizing, and brightening.

Provided is a composition for preventing, ameliorating, or treating ligament or tendon diseases comprising tendon-derived Extracellular Matrix (ECM) powder as an active ingredient, wherein a content of TIMP-1 protein contained in 1 mg of the tendon-derived ECM powder is 500 pg or more.

This invention provides a camellia seed diglyceride microcapsule, its preparation method, and its application, belonging to the field of cosmetic raw material preparation technology. The invention uses a three-dimensional network cross-linked polymer of sea fennel extract, BOXER, and recombinant collagen as the wall material. Recombinant collagen provides the macromolecular framework, and BOXER can cross-link with the recombinant collagen, optimizing the three-dimensional network structure of the wall material and filling the cross-linking sites. The polyphenols contained in the sea fennel extract participate in hydrogen bonding / covalent cross-linking, forming a dense three-dimensional network structure, increasing the mechanical strength of the wall material and encapsulating the camellia seed diglyceride core material, thus improving the stability and antioxidant properties of the camellia seed diglyceride. Sea fennel extract has excellent repair and anti-aging effects, promoting skin cell regeneration; BOXER can promote the synthesis of extracellular matrix glycosaminoglycans, strengthening skin firmness; and recombinant collagen can replenish lost collagen in the skin, improve skin elasticity, and enhance the anti-aging performance of the camellia seed diglyceride microcapsules.

This invention provides the use of Cm-CATH2 in the preparation of drugs for treating silicosis, belonging to the field of biomedical technology. This invention provides the application of Cm-CATH2 and / or pharmaceutically acceptable salts of Cm-CATH2 in the preparation of drugs for treating silicosis, and verifies the therapeutic effect of Cm-CATH2 on silicosis animal models by constructing such models. The results show that Cm-CATH2 can act on silicosis at multiple targets after the early stage of silicosis in animal models. It reduces oxidative stress levels by downregulating lactate dehydrogenase (LDH), downregulates matrix metalloproteinase 2 (MMP2) and extracellular matrix glycosaminoglycans (GAG), and ultimately reduces collagen III (COL-III) levels, thereby achieving an anti-fibrotic effect. This multi-target approach can effectively alleviate fibrosis progression. Therefore, Cm-CATH2 can be used to treat silicosis, and a dose-response effect exists, with good efficacy at high doses.